Do stem cell transplants work for Parkinson's?

Do stem cell transplants work for Parkinson's today?

Completed clinical evidence is highly uncertain and does not settle whether stem cell transplants improve movement or slow Parkinson's disease. A systematic review, which is a study that synthesises all available research on a topic, of 21 studies concluded that the overall certainty of the evidence is very low. Most completed trials have been extremely small, open-label, and lack comparison groups to rule out the placebo effect. A trial registration, NCT05635409, has not yet reported results.

Small, uncontrolled trials dominate the current evidence, meaning we do not know if the transplants cause clinical changes. For instance, a trial at Kyoto University Hospital transplanted reprogrammed adult cells, which are adult cells genetically modified back into an embryonic-like state, into seven patients, but evaluated only six; although four patients showed improved motor scores after 24 months, there was no control group. Similarly, an open-label trial of bemdaneprocel, which is an investigational dopamine cell product derived from human embryonic stem cells, tracked 12 patients; although the seven patients receiving a high dose of 2.7 million cells improved their movement scores by 23 points at 18 months, the study lacked a comparison group.

The only randomised, placebo-controlled trial of bone-marrow-derived stem cells produced highly contradictory results. This phase II trial in Houston enrolled 45 patients to test three intravenous infusions of mesenchymal stem cells, which are stem cells harvested from a donor's bone marrow. Patients receiving three infusions improved by 16.9 points on movement scales at 62 weeks, compared with 14.6 points for the placebo group, but patients receiving two infusions actually fared worse than placebo, improving by only 3.9 points. Because researchers lacked a validated potency assay, which is a laboratory test used to check consistency between manufactured cell batches, nobody has tested why these results were so inconsistent.

What happened to the people who received fetal cell transplants in earlier trials?

Fetal tissue transplants in the 1990s showed that cell replacement could work, but subsequent rigorous trials failed to replicate these benefits. While early open-label trials showed that transplanted ventral mesencephalon tissue could survive for up to 24 years, two major double-blind, placebo-controlled trials funded by the National Institutes of Health in 2001 and 2003 showed no statistically significant clinical benefits compared to a sham surgery.

The risk of graft-induced dyskinesia, which is a side effect of involuntary writhing movements triggered by the transplant, halted widespread adoption. This complication affected 15% to 54% of patients across the two NIH trials, and was so severe that several patients required deep brain stimulation, which is an invasive surgery where electrodes are implanted in the brain, to control the movements. Unlike standard medication side effects, this dyskinesia occurs during the off-state when standard medication has worn off, and predominantly affects the lower limbs.

Tissue contamination and brain sensitivity are the primary causes of this permanent side effect. Fetal tissue contains both dopamine-producing cells and serotonergic cells, which produce the chemical serotonin. Because surgeons could not separate these cell types, transplanted tissue often contained too many serotonergic neurons, which overstimulated surrounding brain pathways. Additionally, years of taking levodopa makes brain cells highly sensitive to dopamine, meaning that small, concentrated grafts create localized hot spots of excessive dopamine release that trigger erratic movements.

What do the newest trials of lab-grown dopamine cells actually show?

Embryonic stem cell trials have reported early results, but they are limited by small, uncontrolled designs. A single-centre, open-label trial, which is a study where both patients and doctors know which treatment is being given, tested embryonic-derived progenitor cells in 12 patients. Although motor scores improved at 12 months, the tiny sample split between a low-dose group of six patients and a high-dose group of six patients makes it impossible to draw definitive conclusions. Similarly, an open-label trial of the product bemdaneprocel split 12 patients into low-dose and high-dose cohorts; while the high-dose group of seven patients improved their motor scores by 23 points at 18 months, the study lacked a comparison group.

Several embryonic stem cell trials exist only as registrations with no published results. The European STEM-PD trial is a phase I trial registration, which is a public record of a planned study that has not yet reported results, designed to test cryopreserved cells in eight patients in Sweden and the United Kingdom. Another trial registration, known as the Dopason study, is currently recruiting patients with moderately severe Parkinson's disease to test bilateral transplants but has not published any results.

Induced pluripotent stem cell trials also rely on tiny, open-label cohorts. A phase I/II trial at Kyoto University Hospital evaluated seven patients who received reprogrammed cells. Out of six patients evaluated at 24 months, four showed improvements in motor scores, but the study lacked a control group. Multiple other pluripotent stem cell trials are active only as registry entries with no results, including the phase I/II trial registration NCT07166757, which is recruiting six to 12 patients, and the phase I/II trial registration NCT06482268.

What surgical and immune risks do these transplants involve?

Brain surgery to transplant cells into the brain carries inherent physical hazards. In an open-label trial of 11 patients who received fetal tissue transplants, three procedure-related serious complications occurred, including two brain haemorrhages and one surgical wound splitting open. In a separate trial of 12 patients receiving embryonic stem cells, one patient experienced a seizure within 24 hours of surgery.

Protecting transplanted cells from the body's immune system requires potent drugs that carry their own side effects. In the 11-patient fetal tissue trial, two participants developed drug-related complications: one experienced severe colitis and another developed Kaposi's sarcoma, a type of cancer causing skin lesions, though both resolved after modifying the drug doses. In a separate trial of seven patients receiving reprogrammed cells, patients required the immunosuppressive drug tacrolimus for 15 months; three of these patients suffered complications linked to the drug, including kidney impairment and liver impairment.

The risk of transplanted cells growing out of control or forming tumours is a critical safety concern, though no human studies have yet documented this happening. Brain scans of 12 patients receiving embryonic stem cells showed no tumours or abnormal tissue overgrowth at 18 months, and scans of seven patients receiving reprogrammed cells showed no abnormal growths at 24 months. However, because these clinical trials have followed patients for only a few years, nobody has yet established whether transplanted cells will remain safe or survive over a lifetime.

Are private commercial stem cell clinics offering the same treatment?

The retrieved scientific sources do not directly address unregulated private stem cell therapies or contrast them with regulated trials. Instead, the medical literature details registered trials that vary widely in the types of cells used and how they are delivered. In highly regulated trials, researchers use specialised dopaminergic progenitors surgically transplanted into deep brain structures. For example, a phase I trial surgically grafted human embryonic cells into the brains of 12 patients, while a trial of seven patients surgically transplanted reprogrammed adult cells.

Other clinical trials test general stem cells delivered through non-surgical routes like nasal sprays, spinal injections, or veins. A pilot trial evaluated fat-derived cells in nine participants by injecting them directly into the forehead and facial regions. Another phase I trial of 18 participants tested neural stem cells delivered as a nasal spray, while a trial registration describes a planned study to transfer bone-marrow-derived stem cells into the veins and nasal passages of participants.

The clinical evidence for all these delivery routes remains early and highly limited, with no large phase III trials completed. The highest level of evidence is a phase II randomised trial, which tested intravenous donor bone marrow stem cells in 45 patients. Although three infusions met the statistical threshold for efficacy, the findings are limited because the placebo group also showed a prominent improvement. Most of the remaining clinical data comes from very small, open-label trials that followed fewer than 15 patients.

What this does not show

Stem cell transplantation has failed to show clear clinical benefits in rigorous, controlled trials. The phase IIb NTCELL trial tested pig-derived brain cells in 18 patients but failed to improve off-medication motor scores, showing no benefit after 104 weeks. Similarly, the TransEuro trial evaluated fetal cell transplants in 11 patients and found no overall clinical improvement after three years compared to a 16-patient control group.

Even where trials claim success, the margins are tiny and skewed by massive placebo responses. In a 2025 randomised trial of 45 patients, those receiving three intravenous donor cell infusions improved by 16.9 points, but the placebo group improved by 14.6 points, leaving a real difference of just 2.3 points. Confusingly, patients receiving two infusions improved by only 3.9 points, faring significantly worse than the placebo group.

Prominent claims often rest on tiny, uncontrolled studies or registrations with no results. Recent reports on reprogrammed cells are based on open-label trials of only six patients, and a trial of embryonic-derived bemdaneprocel followed only 12 patients. The European STEM-PD trial registration is highly publicised but has not yet reported clinical results. Other active trial registrations, including a Chinese study of autologous cells and a US-based study of autologous neurons, have also not reported clinical findings. Finally, a 2022 meta-analysis concerning integrated Chinese and Western medicine for Parkinson's disease was retracted in 2023, and our search identified no retracted papers specifically concerning stem cell transplants.

This review provides you with the exact participant numbers and design limitations of current stem cell trials to help guide your research. Only a clinician can help you weigh these highly uncertain and risky experimental procedures against your individual medical history.